Breast Cancer

Pharmacists guide HR+ breast cancer CDK4/6 therapy, tackling interactions, costs, and toxicity monitoring, and applying new clinical trial insights.

Tucatinib triplet regimen with trastuzumab and capecitabine boosts survival and cerebrospinal fluid control in HER2-positive breast cancer leptomeningeal metastasis.

ADCs are reshaping metastatic breast cancer and pharmacists' roles in treatment management.

Oral bacteria such as Fusobacterium nucleatum may fuel breast cancer. Here's what pharmacists should know about periodontal health and genetic risk.

HER2 breast cancer vaccine boosted by CD27 sparked durable CD4 memory and dramatic tumor regression in studies.

Expanded Medicaid coverage has been linked to access to early diagnosis, timely treatment, and continuity of care in breast cancer.

NCCN-backed MammaPrint stratifies HR+ breast cancer, pinpointing who needs anthracyclines and how pharmacists help personalize oncology care.

Dato-DXd is a promising first-line treatment for metastatic triple-negative breast cancer, enhancing patient outcomes.

FDA grants priority review for gedatolisib, a promising treatment for advanced HR+/HER2– breast cancer, showcasing significant efficacy in recent trials.

New research reveals PUF60's critical role in triple-negative breast cancer, highlighting RNA splicing as a promising therapeutic target for oncology.

Pitavastatin shows promise as a novel treatment for triple-negative breast cancer, enhancing chemotherapy efficacy and targeting cancer cell survival pathways.

Explaining megestrol acetate's dual role in managing symptoms and enhancing treatment efficacy for estrogen receptor–positive breast cancer.

New research links ultra-processed foods, especially processed meats, to higher breast cancer mortality among Black women, highlighting dietary changes for better outcomes.

Pharmacists explore new breast cancer therapies and management strategies, enhancing patient care and treatment outcomes at SABCS.

GLP-1 medications show promise in reducing chemotherapy side effects and improving heart health in breast cancer patients, warranting further research.

Discover how GLP-1 receptor agonists may benefit breast cancer patients by promoting weight loss and improving long-term health outcomes.

Explore the latest insights on breast cancer treatment, focusing on radiation, endocrine therapy, and the role of pharmacists in patient care.

New findings at SABCS reveal MammaPrint's role in identifying early-stage breast cancer patients who benefit from anthracyclines, reducing unnecessary treatment.

Kelly Gable, professor and director of well-being and resilience at Southern Illinois University Edwardsville School of Pharmacy, discusses her own cancer journey and how pharmacists need to be more involved and proactive in patients' mental health.

Explore innovative biomarkers to enhance immunotherapy for early-stage TNBC, aiming to improve patient outcomes and treatment precision.

Project Optimus transforms cancer treatment by optimizing dosing strategies, enhancing efficacy, and reducing toxicities in modern therapies.

New research uncovers diverse tumor subgroups in triple-negative breast cancer, paving the way for personalized treatment strategies and improved patient outcomes.

New studies reveal a modest, temporary increase in breast cancer risk linked to hormonal contraceptives, emphasizing the need for informed patient counseling.

New findings suggest omitting radiation therapy in postmastectomy breast cancer treatment enhances survival, emphasizing the role of systemic therapies.

Researchers explore HER3-targeted therapy with patritumab deruxtecan to enhance outcomes in early-stage triple-negative breast cancer, reducing chemotherapy side effects.